Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Antimalarial activity of Garcinia mangostana L rind and its synergistic effect with artemisinin in vitro

BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201717:131

https://doi.org/10.1186/s12906-017-1649-8

Received: 14 September 2016

Accepted: 23 February 2017

Published: 28 February 2017

Abstract

Background

Malaria especially falciparum malaria still causes high morbidity and mortality in tropical countries. Several factors have been linked to this situation and the most important one is the rapid spread of parasite resistance to the currently available antimalarials, including artemisinin. Artemisinin is the main component of the currently recommended antimalarial, artemisinin based combination therapy (ACT), and it is a free radical generating antimalarial. Garcinia mangostana L (mangosteen) rind contain a lot of xanthone compounds acting as an antioxidant and exhibited antimalarial activity. The aim of this study was to evaluate the antimalarial activity of mangosteen rind extract and its fractions and their interaction with artemisinin against the 3D7 clone of Plasmodium falciparum in vitro.

Methods

Dry ripe mangosteen rind was extracted with ethanol followed by fractionation with hexane, ethylacetate, buthanol, and water consecutively to get ethanol extract, hexane, athylacetate, buthanol, and water fractions. Each of these substances was diluted in DMSO and examined for antimalarial activity either singly or in combination with artemisinin in vitro against Plasmodium falciparum 3D7 clone. Synergism between these substances with artemisinin was evaluated according to certain formula to get the sum of fractional inhibitory concentration 50 (∑FIC50).

Results

Analysis of the parasite growth in vitro indicated that IC50 of these mangosteen rind extract, hexane, ethylacetate, buthanol, and water fraction ranged from 0.41 to > 100 μg/mL. All of the ∑FIC50 were <1.

Conclusions

This study demonstrated a promising antimalarial activity of the extract and fractions of G.mangostana L rind and its synergistic effect with artemisinin. Further study using lead compound(s) isolated from extract and fractions should be performed to identify more accurately their mechanism of antimalarial activities.

Keywords

Garcinia mangostana Artemisinin Antimalarial Synergism in vitro

Background

Malaria remains a major public health issue worldwide despite a decreasing trend in its morbidity and mortality between 2000 and 2015. In 2015, WHO reported 214 million clinical cases with 438.000 death and approximately 3.3 billion population or half of the world population are at risk. Most malaria cases were caused by Plasmodium falciparum and Plasmodium vivax but most of the death was caused by Plasmodium falciparum infection [1]. The persistently high morbidity and mortality of malaria is due to the rapid speed of drug resistant parasite including the currently used artemisinin combination therapy (ACT) [2].

Artemisinin, the main component of ACT, is a free radical generating antimalarial [3] that has a short half life [46], and rapidly clear the parasite [7]. Its single prescription is not recommended due to recrudescence rate [8], and therefore several partner drugs with longer half life are now available such as in artemeter-lumefantrine, dihydroartemisinin-piperaquine, artesunate-mefloquine, artesunate-amodiaquine. Unfortunately resistance of the parasite to the partner drugs has also been reported [911].

Xanthones are potent antioxidant [12], and they possibly reduce the free radical over production in malaria especially if artemisinin is used to manage the disease. On the other side, these compounds can also inhibit heme polymerization [13] that is needed by the parasite to detoxify the heme over production. Our previous study revealed that alpha-mangostin and gamma-mangostin are both xanthone compounds, and exhibited antimalarial activities with synergistic effect with artemisinin [14].

Garcinia mangostana L (mangosteen) grows in tropical area [15], where malaria is endemic. Its general name is mangosteen (English), manggis (Indonesia), and its taxonomic profile is: Magnoliophyta division, Magnoliopsida class, Dilleniidae subclass, Theales order, Clusiaceae family, Garcinia genus, Garcinia mangostana L. species. Its rind, usually a waste product, contained a lot of xanthone compounds [16, 17] and therefore may be developed as alternative drug to treat malaria. This study aims to explore the potential of mangosteen rind as partner drug of artemisinin for treating malaria.

Methods

Plant collection and preparation

Identification of this plant was done by Mr. Djuandi, a curator at the Herbarium Bandungense, Sekolah Tinggi Imu Hayati, Bandung Institute of Technology (ITB), Bandung, Indonesia. A voucher specimen of this material has been deposited in a publicly available herbarium, the Herbarium Bogoriense, Research Center of Biology, Indonesian Institute of Sciences by Dr. J S Rahajoe in 2012 with deposition number of 1143/IPH.1.02/lf.8/VII/2012. The fresh ripe G.mangostana L fruit which had purple color was collected from Subang District, West Java, Indonesia. The fruit was washed with tap water gently and its rind without kernel and seed inside was carefully analyzed for debris and content. The rind was cut into small pieces, air dried, and pulverized into powder. The powder was then macerated with absolute ethanol and subsequently evaporated to obtain the paste like extract according to standard procedure [18]. The extract was then fractionated using hexane to obtain hexane fraction following the same procedure [18]. The hexane fraction obtained was then re-fractionated using ethylacetate to obtain ethylacetate fraction. This procedure was continued using buthanol and water consecutively to obtain buthanol and water fraction. All of these extract and fractions were stored in the - 20 °C freezer until used. To examine the antimalarial activity, each of these substances was dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich, IL, USA) to make a stock solution separately.

Parasite cultivation and determination of 50% Inhibitory Concentration (IC50) of G. mangostana L rind extracts, hexane, ethylacetate, buthanol, and water fractions against P. falciparum 3D7 clone

To determine the antimalarial activity of these extracts and fractions, malarial parasites, P. falciparum 3D7 clone was obtained from the Malaria Laboratory, The Eijkman Institute for Molecular Biology, Jakarta, and was propagated in vitro in duplicate in a 24 well culture plate in the presence of a wide concentration ranges of each extracts and fractions following the procedure described previously [19]. The Red Blood Cell (RBC) used for the propagation of the parasites was a left over or outdated RBC provided by the Indonesian Red Cross, Surabaya, Indonesia without any personal identity except for the type of blood. The parasites concentration in vitro was calculated before and after 48 h incubation with a wide concentration range of each of the extracts and fractions by determining the amount of parasites per 5000 RBC in Giemsa stained thin blood smear. The parasites growth inhibition was calculated by comparing the parasites concentrations of the treated group with the untreated control. The parasites IC50 of each of the extracts and fractions was determined using probit analysis. The antimalarial activity was classified following the criteria as describe previously [20].

Determination of interaction between artemisinin and G. mangostana L rind extracts, hexane, ethylacetate, buthanol, and water fractions as antimalarial against P. falciparum 3D7 clone in vitro

The parasites was cultivated in duplicate in the presence of a wide concentration range of combination of artemisinin and each of these extract sand fractions in 1:1 concentration ratio. The parasites growth before and after 48 h incubation was evaluated by measurement of the parasites concentration in Giemsa stained thin blood smear and the growth inhibition as well as the IC50 was determined using the aforementioned procedure. Interaction between artemisinin and each of these extracts and fractions was determined according to the sum of fractional 50% inhibitory concentration (FIC50) of artemisinin and each of these extracts and fractions according to formula: Ac/As + Bc/Bs, where Ac and Bc are the concentration of A and B in the combination associated with a particular level of effect, e.g., IC50, while As and Bs are the concentration of A and B when are used singly to produced the same level of effect. If this sum is 1, the interaction of these drugs is named additive interaction. Synergistic interaction is named if this sum is less than 1 and if this sum is more than 1, it is named antagonistic interaction [21].

Results

Proximate analysis

Proximate analysis of dry G.mangostana L rind is shown in Additional file 1. The rind extracts mainly contained carbohydrate, crude fibre, and ash.

In vitro antimalarial activity of G. mangostana L extracts and its fractions against 3D7 clone of P. falciparum

The parasites growth in the presence of different concentration of its extracts, hexane, ethylacetate, buthanolic, and water fractions is shown in Additional files 2, 3, 4, 5 and 6 respectively. Analysis of the parasites growth revealed that the IC50 of the extracts, hexane, ethylacetate, buthanolic, and water fractions, ranged from 0.42 μg/mL (ethanolic extract), 0.12 μg/mL (hexane fraction), 1–10 μg/mL (ethylacetate fraction), 1152 μg/mL (buthanolic fraction) to > 100 μg/mL (water fraction).

In vitro interaction between artemisinin and G. mangostana L rind extract and its fractions as antimalaria against 3D7 clone of P. falciparum

The parasite growth in the presence of combination of artemisinin and the extract, hexane, ethylacetate, buthanolic, and water fraction is shown in (Additional files 7, 8, 9, 10 and 11). Analysis of the parasite growth revealed the IC50 ranged from 0,00001 to 0,0001 μg/mL.

Discussion

In vitro antimalarial activity of G.mangostana L rind extract and its fractions

The present study demonstrates a promising antimalarial activity of the extract, hexane, and ethylacetate fraction of the rind of G.mangostana L with the IC50 of less than 10 μg/mL. However, the buthanolic and water fractions revealed a very weak antimalarial activities. The results of this study therefore deserves further exploration to identify the lead compounds that may underline the antimalarial activity. The G.mangostana L. rind contains many kinds of phenolic compounds such as tannins, anthocyanins, xanthones, and their derivates [2225]. The most abundant xanthones in G.mangostana L. rind are alpha-mangostin and gamma-mangostin [26]. These xanthones and other xanthones such as garcinone C and garcinone D also existed in the rind, and have been reported to exhibit active antimalarial activities [14]. Therefore we may conclude that the antimalarial activity exhibited by the rind extract and fractions are caused by the existence of alpha-mangostin, gamma-mangostin, garcinone C, and garcinone D in the rind. Further, the antimalarial activity of xanthones was previously associated with the interference with the heme polymerizationin the malarial parasite [13]. It was reported that xanthones form soluble complex with heme dimmers so that it increases osmotic pressure in the parasite food vacuole causing parasite lysis and death [27]. G. mangostana L rind ethanolic extract also interrupts the tricarboxylic acid (TCA) metabolism of the parasite as indicated by the absence of malate product in the culture medium [28].

In vitro interaction between artemisinin and G. mangostana L rind extract and its fractions as antimalaria against 3D7 clone of P. falciparum

All kinds of combination of the extract and fractions with artemisinin showed a very strong antimalarial activity as indicated by the IC50 which was < 0,001 μg/mL and the sum of FIC50 which was in the range of 0,03 – 0,25, which means synergistic interaction (Additional file 12). Similar finding was also reported in our previous in vitro study using pure compounds of alpha-mangostin, gamma-mangostin, garcinone C and garcinone D [14]. Other in vitro study also demonstrated that the synergistic effect between hydroxycalabaxanthone and artesunate [29]. As the studies using the relatively pure compounds, we therefore could suggest that the synergistic antimalarial activity exhibited in our study using extract and fractions are caused by the existence of similar compounds.

Conclusion

This study demonstrated a promising antimalarial activity and its synergistic antimalarial activity of the extract and fractions of G.mangostana L rind with artemisinin. Further study using lead compound(s) isolated from extract and fractions should be performed to identify more accurately their mechanism of antimalarial activities.

Abbreviations

ACT: 

Artemisinin based combination therapy

DMSO: 

Dimethylsulfoxide

FIC50

Fractional 50% inhibitory concentration

IC50

50% inhibitory concentration

TCA: 

Tricarboxylic acid cycle

Declarations

Acknowledgements

The financial support of the Directorate General of Higher Education of Indonesian Ministry of Education is gratefully acknowledged. The author thank to Prof.dr. Syafruddin, Ph.D. from Eijkman Institute-Jakarta who provided the writing advice and to Wiwied Ekasari, Ph.D as a Coordinator of Malaria Laboratory, Airlangga University, Surabaya, who provided the technical support.

Funding

This study was fully financially supported by the Directorate General of Higher Education of Indonesian Ministry of Education.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its Additional files].

Authors’ information

As the author, I am chairing the Bandung Indonesian Parasitic Disease Control Association, work as a lecturer and Tropical Disease Coordinator of Medical Research Centre at Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.

Competing interests

I as the author declare that there are no competing interests.

Consent for publication

This consent was not relevant for this sudy.

Ethics approval and consent to participate

This study has been approved by dr. Diana Krisanti Jasaputra, Ph.D. and Wahyu Widowati, Ph.D as Ethic Committee of Faculty of Medicine, Maranatha Christian University-Immanuel Hospital Bandung. Consent to participate was not relevant for this study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Faculty of Medicine, Maranatha Christian University

References

  1. World Malaria Report WHO. 2015. Available from http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/. Accessed 2 Aug 2016.
  2. WHO. Antimalarial drug resistance. Available from http://www.who.int/malaria/areas/drug_resistance/overview/en/. Accessed 2 Aug 2016.
  3. Antoine T, Fisher N, Amewu R, O’Neill PM, Ward SA, Biagini GA. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother. 2014;69(4):1005–16.View ArticlePubMedGoogle Scholar
  4. Ilett KF, Batty KT, Powell SM, Tran QB, Le TAT, Hoang LP, et al. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol. 2002;53(1):23–30.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Nealon C, Dzeing A, Müller-römer U, Planche T, Sinou V, Kombila M, et al. Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe Malaria. Antimicrob Agents Chemother. 2002;46(12):3933–9.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Karbwang J, Na-Bangchang K, Tin T, Sukontason K, Rimchala W, Harinasuta T. Pharmacokinetics of intramuscular artemether in patients with severe falciparum malaria with or without acute renal failure. Br J Clin Pharmacol. 1998;45(6):597–600.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Linares M, Viera S, Crespo B, Franco V, Gómez-Lorenzo MG, Jiménez-Díaz MB, et al. Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay. Malar J [Internet]. 2015;14(1):441. Available from: http://www.malariajournal.com/content/14/1/441.View ArticleGoogle Scholar
  8. Giao PT, Binh TQ, Kader PA, Long HP, Van Thang N, Van Nam N, et al. Artemisinin for treatment of uncomplicated falciparum malaria : is there a place for monotherapy ? Am J Trop Med. 2001;65(6):690–5.Google Scholar
  9. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparummalaria in Cambodia: A multisite prospective cohort study. Lancet Infect Dis [Internet]. 2016;16(3):357–65. Available from: http://dx.doi.org/https://doi.org/10.1016/S1473-3099(15)00487-9.View ArticleGoogle Scholar
  10. Färnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E, et al. Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania. Malar J [Internet]. 2012;11(1):176. Available from: https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-11-176.
  11. Tun KM, Jeeyapant A, Imwong M, Thein M, Aung SSM, Hlaing TM, et al. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J [Internet]. 2016;15(1):185. Available from: http://malariajournal.biomedcentral.com/articles/https://doi.org/10.1186/s12936-016-1240-7.View ArticleGoogle Scholar
  12. Zarena AS, Sankar KU. Screening of xanthone from mangosteen (Garcinia mangostana L.) peels and their effect on cytochrome c reductase and phosphomolybdenum activity. J Nat Prod. 2009;2:23–30.Google Scholar
  13. Ignatushchenko MV, Winter RW, Riscoe M. Xanthones as antimalarial agents: stage specificity. Am J Trop Med Hyg. 2000;62(1):77–81.PubMedGoogle Scholar
  14. Tjahjani S, Widowati W. Potensi beberapa senyawa xanthone sebagai antioksidan dan anti-malaria serta sinergisme dengan artemisinin in Vitro. Indonesian Med J. 2013;63(3):95–9.Google Scholar
  15. Morton JF. Mangosteen. In: Morton JF. Fruits of Warm Climates. 2004. 1439–1446. Available from http://www.pssurvival.com/ps/plants/Crops_Fruits_Of_Warm_Climates_2004.pdf. Accessed 2 Aug 2016.
  16. Pedraza-Chaverri J, Rodríguez NC, Ibarra MO, Rojas JMP. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol. 2008;46:3227–39.View ArticlePubMedGoogle Scholar
  17. Zhang Y, Song Z, Hao J, Qiu S, Xu Z. Two new prenylated xanthones and a new prenylated tetrahydroxanthone from the pericarp of Garcinia mangostana. Fitoterapia. 2010;81(6):595–9.View ArticlePubMedGoogle Scholar
  18. Mahdi S, Altikriti Y. Extraction of Natural Products. Sweden: Biologiskt Aktiva Natuprodukter, Uppsala University; 2010. http://www.fkog.uu.se/course/a/biolakt/biolakt-archive/BiolAkt%202010-2/StudentpresentationerHT2010%20(kopia)/BiolAktHT2010_ExtraktionNatProd_Yassir_Suzan/Extraction%20of%20natural%20products_files/Page470.htm. Accessed 27 July 2016.
  19. Budimulja AS, Syafruddin D, Tapchaisri P, Wilariat P, Marzuki S. The sensitivity of Plasmodiumprotein synthesis to prokaryotic ribosomal inhibitors. Mol Biochem Parasitol. 1997;84:137–41.View ArticlePubMedGoogle Scholar
  20. Ramalhete C, Lopes D, Mulhovo S, Rosario VE, Ferreira MJU. Antimalarial activity of some plants traditionally used in Mozambique. Workshop Plantas Medicinais e Fitoterapeuticas nos Tropicos. IICT/CCCM, 29, 30 e 31 de Outubro de 2008. Available from http://www2.iict.pt/archive/doc/C_Ramalhete_wrkshp_plts_medic.pdf. Accessed 3 Aug 2016.
  21. Nandakumar DN, Arun V, Vathsala PG, Rangarajan P, Nandakumar DN, Nagaraj VA, et al. Curcumin-artemisinin combination therapy for malaria. Antimicrob Agents Chemother. 2006;50(5):1859–61.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Maisuthisakul P, Suttajit M, Pongsawatmanit R. Assessment of phenolic content and free radical scavenging capacity of some Thai indigenous plants. Food Chem. 2007;100:1409–18.View ArticleGoogle Scholar
  23. Setyawati NA. Pengaruh perendaman konsentrasi larutan kapur tohor terhadap efektifitas netralisasi rasa pahit pada produk jelly kulit buah manggis. Thesis. Fakultas Teknik, UNNES, Semarang, Indonesia. 2000.Google Scholar
  24. Fu C, Loo AEK, Chia PP, Huang D. Oligomeric proanthocyanidins from mangosteen pericarps. J Agric Food Chem. 2007;55:7689–94.View ArticlePubMedGoogle Scholar
  25. Pebriyanthi NE. Ekstraksi xanthone dari kulit buah manggis (Garcinia mangostana L.) dan aplikasinya dalam bentuk sirup. Skripsi. Fakultas Teknologi Pertanian, Institut Pertanian Bogor, Bogor, Indonesia. 2010.Google Scholar
  26. Walker EB. HPLC analysis of selected xanthones in mangosteen fruit. J Sep Sci. 2007;30:1229–34.View ArticlePubMedGoogle Scholar
  27. Riscoe M, Kelly JX, Winter R. Xanthones as antimalarial agents: discovery, mode of action, and optimization. Curr Med Chem. 2005;12:2539–49.View ArticlePubMedGoogle Scholar
  28. Chaijaroenkul W, Mubaraki MA, Ward SA, Na-Bangchang K. Metabolite footprinting of Plasmodium falciparum following exposure to Garcinia mangostana Linn. crude extract. Exp Parasitol. 2014;145:80–6.View ArticlePubMedGoogle Scholar
  29. Chaijaroenkul W, Na-Bangchang K. The in vitro antimalarial interaction of 9-hydroxycalabaxanthone and α mangostin with mefloquine/artesunate. Acta Parasitol. 2014;60(1):105–11.View ArticlePubMedGoogle Scholar
  30. Tjahjani S. Effect of L-ascorbic acid against host cell and antimalarial activity of artemisinin using MDA and GSH concentration, HUVEC viability, and parasitemia level as parameters. Dissertation. Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia. 2008.Google Scholar

Copyright

© The Author(s). 2017

Advertisement